The medical device specialist lagged the market, and even with a bit of a rebound toward the second half of 2025, shares are ...

I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, ...

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock. Hunterbrook said on Thursday that it has a short position on DXCM ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...